Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes

Trends in Cardiovascular Medicine

Volumn 20, Issue 7, 2010, Pages 211-217

  Ferreiro, José Luis ^a,b   Cequier, Ángel R ^a   Angiolillo, Dominick J ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ANTICOAGULANT AGENT; APIXABAN; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1; DABIGATRAN; DAREXABAN; EV 007; EV 077; INSULIN; NXC 4016; PENTOXIFYLLINE; PICOTAMIDE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RAMATROBAN; RIDOGREL; RIVAROXABAN; SI 8886; SIMVASTATIN; TERUTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; CARDIAC PATIENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PALPITATION; HUMAN; INSULIN TREATMENT; LOADING DRUG DOSE; MAINTENANCE CHEMOTHERAPY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ASPIRIN; DIABETES COMPLICATIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84856359032     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.10.001     Document Type: Review

References (41)

1. Anderson J.L., Adams C.D., Antman E.M., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:e426-e579.
2. Angiolillo D.J., Badimon J.J., Saucedo J.F., et al. A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS)-3 trial. Eur Heart J 2011, 32:838-846.
3. Angiolillo D.J., Bernardo E., Capodanno D., et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease on dual antiplatelet therapy. J Am Coll Cardiol 2010, 55:1139-1146.
4. Angiolillo D.J., Bernardo E., Ramírez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006, 48:298-304.
5. Angiolillo D.J., Capranzano P., Ferreiro J.L., et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011, 106:253-262.
6. Angiolillo D.J., Capodanno D., Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010, 31:17-28.
7. Angiolillo D.J., Capranzano P., Goto S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study. Eur Heart J 2008, 29:2202-2211.
8. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
9. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115:708-716.
10. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81-106. Antiplatelet Trialists' Collaboration.
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
12. Bartnik M., Rydén L., Ferrari R., et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25:1880-1890. Euro Heart Survey Investigators.
13. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000, 102:624-629. CLASSICS Investigators.
14. Bhatt D.L., Marso S.P., Hirsch A.T., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002, 90:625-628.
15. Biondi-Zoccai G.G., Lotrionte M., Anselmino M., et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008, 155:1081-1089.
16. Cadroy Y., Bossavy J.P., Thalamas C., et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000, 101:2823-2828.
17. Capodanno D., Patel A., Dharmashankar K., et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011, 4:180-187.
18. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 2004, 27(Suppl 1):S72-S73. American Diabetes Association.
19. DiChiara J., Bliden K.P., Tantry U.S., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes 2007, 56:3014-3019.
20. Ferreiro J.L., Angiolillo D.J. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009, 102:7-14.
21. Ferreiro J.L., Angiolillo D.J. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011, 123:798-813.
22. Ferreiro J.L., Ueno M., Desai B., et al. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev Esp Cardiol 2011, (Epub ahead of print).
23. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007, 115:3156-3164.
24. Guthikonda S., Lev E.I., Patel R., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007, 5:490-496.
25. James S., Angiolillo D.J., Cornel J.H., et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATELET Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J 2010, 31:3006-3016.
26. Kushner F.G., Hand M., Smith S.C., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120:2271-2306.
27. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942. CURRENT-OASIS 7 Investigators.
28. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358:527-533. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators.
29. Patrono C., García Rodríguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
30. Pignone M., Alberts M.J., Colwell J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010, 55:2878-2886. American Diabetes Association; American Heart Association; American College of Cardiology Foundation.
31. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
32. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005, 294:1224-1232.
33. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007, 167:1593-1599.
34. Steinhubl S.R., Berger P.B., Mann J.T., et al. Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002, 288:2411-2420. CREDO Investigators.
35. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007, 50:1852-1856.
36. Ueno M., Ferreiro J.L., Tomasello S.D., et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 2011, 4:905-912.
37. Webster M.W., Scott R.S. What cardiologists need to know about diabetes. Lancet 1997, 350(Suppl 1):S23-S28.
38. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
39. Wittkowsky A.K. New oral anticoagulants: A practical guide for clinicians. J Thromb Thrombolysis 2010, 29:182-191.
40. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636. TRITON-TIMI 38 Investigators.
41. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.